Pacific's Osteopatch enters US trial:
This article was originally published in Clinica
Pacific Biometrics has completed pilot clinical studies of the Osteopatch skin patch, designed for management of osteoporotic disease. The non-invasive system consists of a patented transdermal sweat collection device, assays for bone loss markers in sweat and a proprietary method for laboratory analysis. A US trial in 300 patients will begin soon and will take three to four months to complete, after which the company will make a 510(k) filing. 28 million people in the US are at risk for osteoporosis, a number that the National Osteoporosis Foundation believes will grow to 41 million by 2015.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.